Publications: Tumor Imaging with HER2


Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer
Lakshmi Sampath, Sunkuk Kwon, Shi Ke, Wei Wang, Rachel Schiff, Michel E. Mawad, and Eva M. Sevick-Muraca
Journal of Nuclear Medicine 48: 1501 (2007)

Sampath et al. synthesized (111In-diethylenetriaminepentaacetic acid [DTPA])n-trastuzumab-(IRDye800)m, a dually labeled conjugate for detecting HER2 overexpression using SPECT and NIR fluorescence imaging. They validated the conjugate in preclinical mouse models with subcutaneous HER2-positive human breast tumors and observed significantly high accumulation of the imaging agent within the tumor, both in-vivo and ex-vivo. In addition, they demonstrated the ability to deliver the agent intradermally into the lymphatic system for clearance within 24 h. Dual-labeled (111In-DTPA)n-trastuzumab-(IRDye800)m may be an effective diagnostic biomarker capable of tracking HER2 overexpression in breast cancer patients.


Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging Agent
Lakshmi Sampath, Sunkuk Kwon, Mary A. Hall, Roger E. Price and Eva M. Sevick-Muraca
Translational Oncology 3: 307 (2010)

Sampath et al. synthesized and characterized (64Cu-DOTA)n-trastuzumab-(IRDye800)m - a dual-labeled imaging agent to detect HER2 overexpression in breast cancer using PET and NIR fluorescence imaging. In preclinical animal studies, Balb/c mice were subcutaneously inoculated with 4T1.2neu (HER2 positive) and 4T1.2 (HER2 negative) breast cancer cells. Distant organ metastases were observed six weeks later. The dual-labeled agent could successfully image HER2 positive primary tumors and resulting metastases within lung, skin, sketelal muscle and lymph nodes, while reduced uptake was observed within HER2 negative tumor-bearing mice.